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ABSTRACT
Carbohydrate moieties of different glycoproteins, such as cross-reactive carbohydrate determinants (CCDs) and galactose
-1,3-galactose, can induce IgE reactivity with varied clinical significance. In this study, the possible participation of glycan
from wheat gliadin, with respect to its IgE-binding capacity, was investigated in children with food allergies to wheat. Total
IgE and wheat-specific IgE quantification, documentation of history, and/or oral food challenge (OFC) were performed for 52
children. Subjects with positive wheat-specific IgE were characterized as the symptomatic group, never-exposed group, or
asymptomatic group. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and glycan detection in gliadin
were performed. IgE binding to gliadin and deglycosylated gliadin was measured by immunoblotting and ELISA. Gliadin-
specific IgE was detected and correlated with wheat-specific IgE in the symptomatic, never-exposed, and asymptomatic groups.
The glycan range overlapped significantly with the gliadin range. Deglycosylation of gliadin reduced the allergenicity of
gliadin. In gliadin, the allergenicity of the glycan portion was greater in the symptomatic group than in the never-exposed and
asymptomatic groups. We conclude that N-glycan in gliadin might exhibit allergenicity as a possible carbohydrate epitope in
wheat allergy in children.
(Allergy Asthma Proc 36:192–199, 2015; doi: 10.2500/aap.2015.36.3815)
Wheat is one of the most common foods causingfood allergies in children.1,2 Wheat proteins are
classified based on their extraction in different solvents
and include albumin, globulin, gliadin, and glutenin.2
Water- and dilute salt-soluble fractions of wheat (albu-
mins and globulins) comprise only 15%–20% of the
total protein; most of the protein consists of the etha-
nol- and dilute acid-soluble wheat fractions (gliadins
and glutenins).3,4 Gliadins are grouped into three
types, /-, -, and -gliadins.5 Recently, specific IgEs
to -, -, and -gliadin were detected in Baker’s
asthma,4,6,7 to -, and -gliadin in wheat-dependent,
exercise-induced anaphylaxis,8–10 and to gluten (which
contains approximately equal amounts of gliadin and
glutenin) in recurrent urticaria.11 For patients with
food allergies to wheat, specific IgEs to all wheat frac-
tions were detected at various levels.12–16
A glycan is the carbohydrate portion of a glycocon-
jugate, such as a glycoprotein, glycolipid, or a pro-
teoglycan.17 Many or most of the allergens that we
inhale or ingest are glycosylated with oligosaccha-
rides.2,18 Despite this, current evidence shows that the
IgE antibodies associated with allergic disease are spe-
cific for protein epitopes, and most research has fo-
cused on protein epitopes.18
The presence of IgE antibodies to carbohydrate anti-
gens was first identified from in vitro experiments look-
ing at cross-reactivity between different plant-derived
antigens.19 In part because of this approach, the carbo-
hydrate epitopes identified were generally, or exclu-
sively, cross-reactive, which led to the designation
cross-reactive carbohydrate determinants (CCDs).18 It
is well known that the carbohydrate moieties present
in many plant foods can induce antiglycan IgE re-
sponses. However, the clinical significance of these
CCDs is unclear.19,20 By contrast, recent work has
shown that IgE antibodies specific for the carbohydrate
galactose--1,3-galactose are capable of eliciting seri-
ous, even fatal, reactions.21,22
In this study, we first aimed to evaluate the allerge-
nicity and glycosylation of gliadin in wheat allergy.
Subsequently, we investigated the possible participa-
tion of the glycan from gliadin of wheat in terms of its
IgE-binding capacity in the sera of children with wheat
allergy.
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Sera were obtained from 52 patients who visited the
allergy clinic for food allergies or other allergic dis-
eases at the Severance Hospital of Yonsei University
and Ilsan Paik Hospital of Inje University. After venous
blood was drawn, serum was separated and stored at
20°C until analysis.
In this study, wheat allergy was defined as IgE-
mediated allergy to wheat based on case history,
wheat-specific IgE concentrations, and/or oral food
challenge (OFC). After wheat ingestion, the clinical
reaction history of patients with positive wheat-spe-
cific IgE was categorized into four types: immediate
reaction, no symptoms, never exposed, or unclear
symptoms (Fig. 1). For patients with low wheat-spe-
cific IgE under the predictive diagnostic decision point
(26 kUA/L)
23 and no recent reactions to wheat, OFC
was strongly recommended to assess the status of tol-
erance. For other patients, we could not perform OFC
for various reasons, including recent reactions to
wheat, severe atopic dermatitis, young age, parents’
refusal, or no previous reactions to wheat despite the
presence of high wheat-specific IgE levels.
We divided children who were positive for wheat-
specific IgE and had a clear history about wheat allergy
into three groups according to clinical history and/or
OFC: the symptomatic group, the never-exposed
group, and the asymptomatic group (Fig. 1).
Nine patients with high wheat-specific IgE who had
never consumed wheat due to severe atopic dermatitis
were grouped as the never-exposed group (Table 1)
and five patients who had no symptoms after wheat
ingestion despite high wheat-specific IgE were
grouped as the asymptomatic group (Table 2).
Eight patients who had a clinical history of immedi-
ate hypersensitivity reactions after wheat ingestion
with high wheat-specific IgE above the predictive di-
agnostic decision point, and four patients who showed
positive results to OFC with wheat, were grouped as
the symptomatic group (Table 3).
The sera of 10 patients who had high wheat-specific
IgE levels and unclear histories of wheat allergies were
used to create the wheat-positive pooled serum. These
patients had severe multiple food allergies and severe
atopic dermatitis. Therefore, their symptoms could not
be unambiguously defined as a wheat allergy. The sera
of 16 children who visited the clinic for asthma, allergic
rhinitis, atopic dermatitis, or chronic cough without
food allergies were used as negative pooled serum.
These samples were negative for specific IgEs to all the
evaluated allergens.
The Severance Hospital Institutional Review Board
(4-2013-0317) and the Ilsan Paik Hospital Institutional
Review Board (IB-2-1308-038) approved this study, and
informed consent was obtained from the parents of the
children.
ImmunoCAP Test for Total and Specific IgE to
Wheat
Total and wheat-specific IgE levels were measured
using the ImmunoCAP test (Pharmacia, Diagnostics,
Uppsala, Sweden). For those patients whose sera were
used to create the negative pooled serum, levels of
specific IgE to Alternaria, Dermatophagoides pteronyssi-
nus, Dermatophagoides farinae, pollen, or other foods
according to their clinical history were measured in-
stead of wheat-specific IgE. According to the manufac-
turer’s instructions, specific IgE levels of over 0.35
kUA/L were considered positive.
Open OFCs to Wheat
OFC to wheat was performed as an open challenge in
a hospital setting and supervised by a physician in
accordance with the guidelines of the Korean Academy
of Pediatric Allergy and Respiratory Diseases.24 Pa-
tients were challenged with boiled wheat noodles. The
total dose of wheat noodles for OFC was adjusted
according to age (90–200g). The test was started by
consuming one strand of boiled wheat noodles (1.353
g), and this amount was doubled every 15 minutes
until symptoms arose or until the entire test meal was
consumed.
Sodium Dodecyl Sulfate-Polyacrylamide Gel
Electrophoresis (SDS-PAGE) of Gliadin
Gliadin (Sigma-Aldrich, St. Louis, MO) was pur-
chased commercially. Gliadin (10 g) was dissolved in
sample buffer (60mM Tris-HCl, 25% glycerol, 2% SDS,
14.4mM 2-mercaptoethanol, and 0.1% bromophenol
blue) and boiled for eight minutes. The denatured
gliadin solution was then loaded and separated on
4%–20% gradient PAGE gels (Mini-PROTEAN TGX
Gel; Bio-Rad, CA), and protein bands were stained
with Coomassie blue. For immunoblotting, sepa-
rated proteins were transferred onto polyvinylidene
difluoride membranes (Immobilon P; Millipore Co.,
Billerica, MA).
Figure 1. Flowchart of study population.






Glycan Detection in Gliadin
Glycans were identified using a commercially avail-
able kit (DIG Glycan Differentiation kit; Roche, Mann-
heim, Germany) following the manufacturer’s instruc-
tions. The specific binding of lectins to carbohydrate
moieties was used to identify glycan and its structure.
IgE Immunoblotting of Gliadin and Deglycosylated
Gliadin
For glycan removal, gliadin was oxidized by soaking
the immunoblot membrane in 20mM NaIO4/50mM
acetate buffer (pH 4.5) for two hours at room temper-
ature. To evaluate gliadin-IgE binding, untreated and







Clinical Symptoms After Ingestion of
Wheat
1 0.6 M AD, FA 5000 100 Never exposed
2 1 M AD, FA 5000 100 Never exposed
3 0.92 M AD 5000 82.1 Never exposed
4 1.75 M AD 5000 100 Never exposed
5 0.75 M AD, FA 773 48.8 Never exposed
6 0.65 M AD 5000 30.4 Never exposed
7 0.53 M AD, AR 1488 73.5 Never exposed
8 2.1 M AD, AR, 3190 38.8 Never exposed
9 2 F AD, FA 5000 100 Never exposed
AD  atopic dermatitis; AR  allergic rhinitis; FA  food allergy.
Table 2. Characteristics of the asymptomatic group (n  5)
Number Age
(years)




Clinical Symptoms After Ingestion
of Wheat
10 2.1 F AD, FA 515 73.5 No symptoms
11 0.66 F AD 798 22.4 No symptoms
12 5 M AD, FA 501 22.6 No symptoms
13 2.1 M AD, FA 3757 43 No symptoms
14 2.1 M AD, FA 3606 46.7 No symptoms
AD  atopic dermatitis; FA  food allergy.
Table 3. Characteristics of the symptomatic group (n  12)
Number Age
(years)




Clinical Symptoms After Ingestion of
Wheat (OFC Reaction)
15 1.3 F AD, FA 151 10.9 AE
16 7.5 M AD, AR, FA 1124 9.26 U
17 6.1 M AD, AR, BA, FA 1422 32.9 Ana
18 1 M AD, BA, FA 42.7 0.67 (U)
19 5 M AD, AR, BA, FA 203 1.49 (U)
20 1 F AD, FA 94 15.9 Ana
21 5 M AD, AR, BA, FA 199 2.17 (U)
22 1 F FA 116 36.6 Ana
23 3 M AD, FA 323 11.1 U, AE
24 2 F AD, CU, FA 219 82.6 Ana
25 2 M AD, FA 296 97.5 Ana
26 1 M AD, FA 289 4.07 (U, Sn)
AD  atopic dermatitis; AE  angioedema; Ana  anaphylaxis; AR  allergic rhinitis; BA  bronchial asthma; CU 
chronic urticaria; FA  food allergy; (Sn)  sneezing during OFC; U  urticaria; (U)  urticaria during OFC; OFC  oral
food challenge.






NaIO4-treated gliadin membranes were reacted with
serum (1:10) overnight at 4°C. The membranes were
incubated for one hour with alkaline phosphatase-la-
beled antihuman IgE antibodies (Sigma-Aldrich). The
membranes were developed in nitro-blue tetrazolium/
5-bromo-4-chloro-3-indolyphosphate solution (Roche
Diagnostics, Mannheim, Germany).
To confirm glycan removal, glycan detection was
performed using a DIG Glycan Differentiation kit
(Roche Diagnostics) following the supplier’s instruc-
tions.
ELISA of Gliadin and Deglycosylated Gliadin
Gliadin was dissolved in 100mM carbonate buffer
(pH 10.0). Gliadin (3 g/mL) was coated onto 96-well
microtiter plates (Costar Co., NY) overnight at 4°C and
then blocked with 1% BSA in PBS for one hour at room
temperature. Diluted serum (1:10) in block buffer was
allowed to react for one hour at room temperature. IgE
was detected by incubation with biotinylated antihu-
man IgE antibody (Vector Laboratories, Burlingame,
CA) for one hour at room temperature, followed by
incubation with streptavidin-conjugated horseradish
peroxidase (R&D Systems, Minneapolis, MN) for 30
minutes. The plates were developed by addition of the
TMB substrate (KPL, Inc., Gaithersburg, MD). The ab-
sorbance at 450 nm was measured with a VersaMax
microplate reader (Molecular Devices, Sunnyvale, CA).
To remove glycan, gliadin adsorbed onto microtiter
plates was oxidized by adding 40mM NaIO4 in 50mM
acetate buffer (pH 4.5).
Statistical Analysis
Data were expressed as mean  SD. Statistical anal-
ysis comparing gliadin, gliadin ratio, and allergenicity
of glycan among different groups were assessed by
Student’s t-test. Statistical analysis comparing IgE
binding with gliadin and to deglycosylated gliadin was
assessed by paired t-test. Correlation coefficients were
determined using the Spearman rank correlation test.
p  0.05 was considered significant. T.W.S., J.Y.H., and
K.E.L. contributed equally to this work.
RESULTS
Proteins, Glycans, and IgE Binding of Gliadin
Protein bands of gliadin ranging from 25 to 60 kDa
were observed (Fig. 2). We observed binding between
gliadin and IgE from wheat-positive pooled serum
through the entire molecular weight range of gliadin.
However, IgE binding was not observed with either
negative pooled serum or buffer control (Fig. 2). The
range of glycan in gliadin overlapped almost com-
pletely with that of gliadin itself (Fig. 2).
Correlation of Wheat-Specific IgE and Gliadin-
Specific IgE in Wheat Allergy
The level of wheat-specific IgE, as detected by the Im-
munoCAP test, was significantly correlatedwith the level
of gliadin-specific IgE detected by ELISA in the symp-
tomatic, never-exposed, and asymptomatic groups (r 
0.64, p  0.026, r  0.75, p  0.020 and r  0.90, p 
0.137, respectively). Although not statistically signifi-
cant, the symptomatic group had a higher proportion
of gliadin than that seen in the never-exposed and the
asymptomatic groups (0.030 versus 0.026, p  0.699
and 0.030 versus 0.025, p  0.812, respectively).
Allergenicity of Gliadin
In the symptomatic, never-exposed, and asymptom-
atic groups, IgE reactivity to gliadin was detected in all
sera and was significantly higher than in the negative
pooled serum (0.98  0.68 versus 0, p  0.001). IgE
reactivity for gliadin was not observed in the negative
pooled serum.
Effect of Deglycosylation on Gliadin Allergenicity
IgE binding to gliadin in wheat-positive pooled se-
rum was detected by immunoblotting and revealed
bands ranging from 25 to 60 kDa. After glycan removal
by NaIO4 treatment, the intensity of the bands de-
creased. In the never-exposed and asymptomatic
groups, IgE binding was observed in all individual
serum samples with bands ranging from 10 to 100 kDa
in immunoblotting. After glycan removal by NaIO4
treatment, the intensity of these bands decreased in
most sera. However, for some sera, the visual decrease
Figure 2. Protein bands of gliadin ranging from 25 to 60 kDa,
separated by SDS-PAGE. The glycan component of gliadin was
detected by the DIG Glycan Differentiation kit, and its molecular
weight range overlapped almost completely with gliadin, from 25 to
60 kDa. IgE binding to gliadin in wheat-positive pooled serum
through the entire molecular weight range of gliadin were observed
by immunoblotting.






was not apparent (Fig. 3 A). Therefore, we reevaluated
this decrease with ELISA. In both the never-exposed
and asymptomatic groups, deglycosylated gliadin was
significantly less recognized by IgE antibodies com-
pared with untreated gliadin [1.75 0.52 versus 1.55
0.49, p 0.001 (Fig. 3 B); 1.09 0.64 versus 0.86 0.57,
p  0.018 (Fig. 3 C)].
In the symptomatic group, IgE binding was observed
in all individual serum samples, with bands ranging
from 25 to 60 kDa detected by immunoblotting (Fig. 4
A). After glycan removal by NaIO4 treatment, the in-
tensity of these bands decreased in most sera. How-
ever, for some sera, an obvious visual decrease was not
observed (Fig. 4 A). Therefore, we confirmed that
deglycosylated gliadin was significantly less recog-
nized by IgE antibodies compared with gliadin, in all
sera from the symptomatic group, by ELISA (0.36 
0.35 versus 0.24  0.29, p  0.001) (Fig. 4 B).
Allergenicity of the Glycan Portion in Gliadin
The binding of IgE to the glycan portion of gliadin
was more pronounced in the symptomatic group than
in the never-exposed group (0.34  0.19 versus 0.12 
0.06, p  0.004) (Fig. 5). Although not statistically sig-
nificant, the binding of IgE to the glycan portion of
gliadin appeared to be higher in the symptomatic
group than in the asymptomatic group (0.34  0.19
versus 0.24  0.17, p  0.341) (Fig. 5).
DISCUSSION
This is the first study to investigate the allergenicity
of glycan, which is present in gliadin as a carbohydrate
epitope, in children with wheat allergy.
Previously, various levels of IgE reactivities to glia-
dins were detected in children with food allergies to
wheat. Mittag et al. reported that seven of eight chil-
Figure 3. Comparison of IgE binding between gliadin and deglycosylated gliadin with sera from the never-exposed (number 1–9) and
asymptomatic (number 10–14) groups, detected by immunoblotting and ELISA. (A) IgE binding was demonstrated in the range 10 to 100
kDa by immunoblotting. After glycan removal by NaIO4 treatment, the band intensity decreased. (B) IgE binding to gliadin measured by
ELISA showed a significant decrease after glycan removal in the never-exposed group. (C) IgE binding to gliadin measured by ELISA showed
a significant decrease after glycan removal in the asymptomatic group.






dren with food allergy to wheat exhibited gliadin-
specific IgE in immunoblotting experiments,16 and Bat-
tais et al. revealed that of 27 patients (14 adults/14
children) with wheat allergies, the percentage of pa-
tients with specific IgE to -gliadin was 7%, to -glia-
din was 20%, to -gliadin was 7%, and to fast -gliadin
was 20% in immunoblotting studies.15 In this study, all
patients with wheat allergy (i.e., the symptomatic
group) showed IgE reactivity to whole gliadin, al-
though two patients showed very weak activity. Our
results demonstrate the importance of whole gliadin as
an allergen for children with wheat allergy, consistent
with previously published data. The differences in per-
centages between our study and previous studies
could be caused by the levels of wheat-specific IgE in
the study population, because wheat-specific IgE levels
correlated with gliadin-specific IgE levels in our study.
IgE reactivity to gliadin might reflect wheat-specific
IgE levels and this could be anticipated, because glia-
din is a fraction of wheat proteins.
Some wheat proteins belonging to both the gliadin
and glutenin families showed reactivity to antibodies
against xylose containing N-glycans. Therefore, these
proteins are thought to be glycosylated.25 However, to
our knowledge, there has been no previous study in-
vestigating the range of glycosylation of gliadins. We
tried to determine the range of gliadins that were gly-
cosylated and observed that the detected glycan over-
lapped with almost the entire range of gliadins. There-
fore, we concluded that the entire range of gliadin
contains glycan.
With respect to carbohydrate allergenicity in wheat
allergy, there have been a few studies examining IgE
binding to well-recognized CCDs, such as horseradish
peroxidase and the N-glycan of bromelain (MUXF), in
Baker’s asthma.4,26 In this study, deglycosylated glia-
din was significantly less recognized by IgE antibodies
compared with intact gliadin, and these results suggest
that glycan may be the carbohydrate epitope of gliadin.
The decreased reactivity of deglycosylated gliadin
Figure 4. Comparison of IgE binding between gliadin and deglycosylated gliadin in sera from symptomatic group, detected by immuno-
blotting and ELISA. (A) IgE binding was demonstrated in the 25 to 60 kDa by immunoblotting. After glycan removal by NaIO4 treatment,
the band intensity decreased. (B) IgE binding to gliadin as measured by ELISA was significantly decreased after glycan removal. AE,
angioedema; Ana, anaphylaxis; U, urticaria; (U), urticaria during OFC.






compared with gliadin could be caused by other un-
proven structural changes of gliadin. Similar to the
current study, previous studies that evaluated the sig-
nificance of the carbohydrate epitope commonly used
NaIO4 oxidation for deglycosylation.
27,28
In this study, IgE binding to the glycan portion of
gliadin was greater in the symptomatic group than in
the never-exposed and asymptomatic groups. These
results also support the significance of the glycan por-
tion of gliadin. This study suggests a possible clinical
significance for the glycan of gliadin, a previously un-
evaluated carbohydrate antigen.
Seven N-linked glycosylation sites have been identi-
fied in wheat protein.29 It is unclear whether the glycan
in gliadin is one of well-recognized CCDs. However,
based on our results, the immunologic significance of
glycan in gliadin appears to be different from that of
well-recognized CCDs, because IgE antibodies to
plant-derived CCDs usually exhibit only minor clinical
significance and lack specificity.19
In conclusion, whole gliadin could be considered an
important allergen for children with wheat allergy, and
the entire range of gliadins are glycosylated. Deglyco-
sylation of gliadin reduced the allergenicity of gliadin.
The N-glycan moiety of gliadin might exhibit allerge-
nicity and act as a carbohydrate epitope in wheat al-
lergy in children.
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Erratum
In the article Serum interleukin 17, interleukin 23, and interleukin 10 values in children with atopic eczema/dermatitis
syndrome (AEDS): Association with clinical severity and phenotype, Allergy Asthma Proc 36, 74–81, 2015; doi: 10.2500/
aap.2015.36.3808, in Table 2 there were some incorrect values within the columns. The revised table is below.
The authors regret the error.
Table 2. Total IgE, IL-17, IL-23, and IL-10 in aAEDS, naAEDS subjects, and heathy controls
N SCORAD Total IgE UI/mL IL-17 pg/mL IL-23 pg/mL IL-10 pg/mL
aAEDS 104 360.7  25.34 72.49  10.00 235.84  65.07 3.28  0.89
Mild 32 20.31  2.2 333.24  23.59 59.30  3.219 180.57  12.25 3.88  0.48
Moderate 37 39.76  9.03 366.02  7.67 74.08  2.54 233.67  13.20 3.678  0.50
Severe 35 56.67  4.52 385.25  6.42 82.87  3.07 288.96  9.58 2.19  0.25
naAEDS 77 69.80  12.29 53.94  0.95 188.02  11.75 3.15  0.22
Mild 25 21.33  2.1 68.37  11.46 50.01  0.86 148.66  8.15 3.91  0.23
Moderate 29 37.21  8.64 67.75  15.45 53.86  0.75 190.12  14.8 3.63  0.20
Severe 23 54.31  2.11 73.3  9.7 57.97  1.25 225.3  12.3 1.93  0.24
Control group 93 — 73.4  20.3 29.3  12.1 111.3  13.4 4.95  0.5
AEDS  atopic eczema/dermatitis syndrome; aAEDS  atopic AEDS; IL  interleukin; naAEDS  nonatopic AEDS;
SCORAD  Score Atopic Dermatitis.
doi: 10.2500/aap.2015.36.9332
Allergy and Asthma Proceedings 199
O N
OT
 CO
PY
